Whitey:
I don't know what the market is expecting out of the ASCO conference in Atlanta a week from this Saturday. BIOM is just going to be mentioned in two papers to be presented, so that is not too much to expect.
If the N.Y. Times comes out with an article on cancer vaccines, at it has been rumored, that is a dog with a different collar, since that could possibly make a big "run up". Just remember what happened with Entremed and the anti-angiogenesis stocks, little RGEN and not so little TCLN included.
Remember also what BIOM's stock did with the article on Fortune last November, even though the buying frenzy lasted less than two hours.
BIOM has said that they plan to take an early look at phase III results 24 months after the start. If the "start" was last November
that means it is only 18 months left, and if the results come as expected, they are planning on asking the FDA for an EXPEDITE APPROVAL.
That means they could start selling the vaccine while they were still continuing with the phase III on breast cancer. Of course if Theratope gets approved for breast cancer, the use for prostate, ovary and colon, could be coming pretty fast afterwards.
Then there is the results of the "bridging study" on some 18 patients with the new more potent vaccine, the results of which are to be released this year.
Again, don't worry and keep buying it on any dips.
It seems to me it did pretty well today in spite the late sell off, taking in account NASDAQ dropped more than 60 points.
Bernard
|
